In the phase 3 PADA-1 trial presented at the 2021 San Antonio Breast Cancer Symposium, it was observed that when switching from an aromatase inhibitor plus palbociclib to fulvestrant and palbociclib upon early identification of the ESR1 mutation in plasma—before disease progression—the median PFS was doubled. Here, CYP19A1 is linked to breast carcinoma.